Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 561Leukemia 282Precursor Cell Lymphoblastic Leukemia-Lymphoma 235Lymphoma 160Myelodysplastic Syndromes 111Burkitt Lymphoma 91Congenital Abnormalities 86Lymphoma, Non-Hodgkin 85Leukemia, Monocytic, Acute 84Leukemia, Myelomonocytic, Acute 82Lymphoma, Large B-Cell, Diffuse 80Leukemia, Erythroblastic, Acute 75Leukemia, Megakaryoblastic, Acute 72Recurrence 70Lymphoma, Mantle-Cell 70Lymphoma, Follicular 49Hodgkin Disease 44Leukemia, Myelomonocytic, Chronic 43Leukemia, Biphenotypic, Acute 43Lymphoma, Large-Cell, Immunoblastic 37Blast Crisis 37Anemia, Refractory, with Excess of Blasts 36Leukemia, Myelogenous, Chronic, BCR-ABL Positive 35Leukemia, Lymphocytic, Chronic, B-Cell 33Myeloproliferative Disorders 30Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 28Lymphoma, B-Cell, Marginal Zone 24Leukemia, Myeloid, Chronic-Phase 23Leukemia, Eosinophilic, Acute 23Leukemia, Basophilic, Acute 22

Interventions

Temozolomide 26Magnetic Resonance Spectroscopy 19Etoposide 14Cyclophosphamide 13Radiotherapy 11Filgrastim 10Bevacizumab 10Carboplatin 9Biopsy 8Cisplatin 7X-Rays 6Thiotepa 6Specimen Handling 6Phantoms, Imaging 6Carmustine 6Radiation 5Nuclear Medicine Department, Hospital 5Nivolumab 5Irinotecan 52-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 5sargramostim 4Vincristine 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4Erlotinib Hydrochloride 4Azacitidine 4olaparib 3etoposide phosphate 3Surveys and Questionnaires 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ependymoma × Cytarabine × Clear all
NCT01356290 2026-02-23

MEMMAT

Medical University of Vienna

Phase 2 Recruiting
232 enrolled
CNS

Ependymoma, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡